Clinical Trial Update: Define Predictors of Response to Ozanimod in UC Discovering Biomarkers in the Management of Ulcerative Colitis

View source ↗

Summary

A ClinicalTrials.gov entry for a study to identify predictors and biomarkers of response to Ozanimod in ulcerative colitis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Zeposia (ozanimod hydrochloride)

Snippet

Sponsor: Beth Israel Deaconess Medical Center | Conditions: Ulcerative Colitis | Status: WITHDRAWN